OKYO Pharma Ltd (OKYO) shareholders
Close on Nov 16, 2026Market cap $61.40MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Point72 Asset Management, L.P. Joint filing with Point72 Capital Advisors, Inc. (7.90%), Steven A. Cohen (7.90%) | 4,058,445 | 7.90% | 13G (passive) | Feb 17, 2026 |
| Alex Silverstein Joint filing with Sirenia Capital Management LP (7.70%) | 4,054,054 | 7.70% | 13G (passive) | Mar 31, 2026 |
| Chernett Jorey | 3,802,194 | 9.50% | 13G (passive) amendment | Dec 31, 2025 |
| Woodline Partners LP | 3,652,190 | 7.00% | 13G (passive) | Mar 31, 2026 |
| Laura Natalia Monica Fonda | 1,928,451 | 5.01% | 13G (passive) | Jul 22, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OKYO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Woodline Partners LP | 3,652,768 | 6.96% | $5.48M | +578 | 0.02% |
| Stonepine Capital Management, LLC | 862,996 | 1.64% | $1.29M | +12,996 | 0.73% |
| Maven Securities LTD | 809,317 | 1.54% | $1.21M | −366,218 | 0.02% |
| Balyasny Asset Management L.P. | 580,596 | 1.11% | $870.89K | −4,200 | 0.00% |
| Opaleye Management Inc. | 375,204 | 0.71% | $562.81K | New | 0.05% |
| UBS Group AG | 55,009 | 0.10% | $82.51K | −4,751 | 0.00% |
| XTX Topco Ltd | 37,769 | 0.07% | $56.65K | +117 | 0.00% |
| Choreo, LLC | 33,255 | 0.06% | $49.88K | New | 0.00% |
| Quantinno Capital Management LP | 33,255 | 0.06% | $49.88K | New | 0.00% |
| Cerity Partners LLC | 12,812 | 0.02% | $19.22K | – | 0.00% |
| Geode Capital Management, LLC | 12,090 | 0.02% | $18.14K | – | 0.00% |
| Renaissance Technologies LLC | 11,200 | 0.02% | $16.80K | New | 0.00% |
| Jane Street Group, LLC | 10,302 | 0.02% | $15.45K | New | 0.00% |
| Steward Partners Investment Advisory, LLC | 6,000 | 0.01% | $9.00K | New | 0.00% |
| EFG International AG | 923 | 0.00% | $1.39K | – | 0.00% |
| Osaic Holdings, Inc. | 152 | 0.00% | $228 | – | 0.00% |
| Continuum Advisory, LLC | 50 | 0.00% | $75 | New | 0.00% |
| Morgan Stanley | 10 | 0.00% | $15 | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 3 | 0.00% | $4 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 19 | 6M | 12.4% | 8 / 3 | 3 / 1 | 0M | 0M |
| Q1 2026 | 12 | 6M | 12.2% | 4 / 2 | 1 / 2 | 6M | 1M |
| Q4 2025 | 10 | 1M | 1.3% | 4 / 1 | 1 / 2 | 0M | 2M |
| Q3 2025 | 8 | 3M | 4.9% | 4 / 0 | 1 / 1 | 0M | 0M |
| Q2 2025 | 5 | 3M | 5.3% | 2 / 1 | 0 / 4 | 1M | 0M |
| Q1 2025 | 7 | 2M | 4.0% | 2 / 1 | 1 / 2 | 2M | 1M |
| Q4 2024 | 7 | 1M | 2.0% | 1 / 2 | 0 / 0 | 0M | 0M |
| Q3 2024 | 6 | 1M | 1.9% | 1 / 0 | 1 / 2 | 0M | 0M |
| Q2 2024 | 7 | 1M | 1.9% | 1 / 1 | 2 / 0 | 0M | 0M |
| Q1 2024 | 6 | 1M | 1.7% | 1 / 2 | 1 / 2 | 0M | 0M |
| Q4 2023 | 7 | 1M | 1.7% | 2 / 2 | 1 / 2 | 1M | 0M |
| Q3 2023 | 7 | 0M | 0.2% | 6 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert John Dempsey | CHIEF EXECUTIVE OFFICER, Director | 15,000 | 0.03% | Aug 7, 2026 |
| Gary S. Jacob | CHIEF DEVELOPMENT OFFICER, Director | 112,420 | 0.21% | Aug 7, 2026 |
| Rajkumar V. Patil | Chief Scientific Officer | 20,030 | 0.04% | Aug 7, 2026 |
| Flavio Mantelli | CHIEF MEDICAL OFFICER | 20,000 | 0.04% | Aug 7, 2026 |
| Keeren Rameshchandra Shah | Chief Financial Officer | 16,667 | 0.03% | Jun 10, 2026 |
| Gabriele M. Cerrone | Director, 10% owner | 21,400,332 | 40.78% | Aug 7, 2026 |
| John P. Brancaccio | Director | 35,201 | 0.07% | Aug 7, 2026 |
| Bernard Denoyer | Director | – | – | Jun 10, 2026 |
| Willy Jules Simon | Director | 15,383 | 0.03% | Jun 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rajkumar V. Patil Chief Scientific Officer | Jul 27, 2026 | Buy | +3,363 | $1.49 | $5.01K | 20,030 |
| Rajkumar V. Patil Chief Scientific Officer | Jul 27, 2026 | Award | +3,363 | $1.49 | $5.01K | 20,030 |
| Robert John Dempsey CHIEF EXECUTIVE OFFICER, Director | Jul 22, 2026 | Buy | +15,000 | $1.54 | $23.10K | 15,000 |
| Robert John Dempsey CHIEF EXECUTIVE OFFICER, Director | Jul 22, 2026 | Award | +15,000 | $1.54 | $23.10K | 15,000 |
| Flavio Mantelli CHIEF MEDICAL OFFICER | Jul 21, 2026 | Buy | +20,000 | $1.40 | $28.00K | 20,000 |
| John P. Brancaccio Director | Jul 21, 2026 | Buy | +5,000 | $1.48 | $7.40K | 35,201 |
| Gary S. Jacob CHIEF DEVELOPMENT OFFICER, Director | Jul 21, 2026 | Buy | +3,500 | $1.40 | $4.90K | 112,420 |
| Gabriele M. Cerrone Director, 10% owner | Jul 21, 2026 | Buy | +22,500 | $1.45 | $32.63K | 10,873,916 |
| Gabriele M. Cerrone Director, 10% owner | Jul 21, 2026 | Award | +22,500 | $1.45 | $32.63K | 10,873,916 |
| Gary S. Jacob CHIEF DEVELOPMENT OFFICER, Director | Jul 21, 2026 | Award | +3,500 | $1.40 | $4.90K | 112,420 |
| John P. Brancaccio Director | Jul 21, 2026 | Award | +5,000 | $1.48 | $7.40K | 35,201 |
| Flavio Mantelli CHIEF MEDICAL OFFICER | Jul 21, 2026 | Award | +20,000 | $1.40 | $28.00K | 20,000 |
| Gabriele M. Cerrone Director, 10% owner | Jul 20, 2026 | Buy | +25,000 | $1.40 | $35.00K | 10,851,416 |
| Gabriele M. Cerrone Director, 10% owner | Jul 20, 2026 | Award | +25,000 | $1.40 | $35.00K | 10,851,416 |
| Gabriele M. Cerrone Director, 10% owner | Jun 8, 2026 | Award | +300,000 | $1.72 | $516.00K | 10,826,416 |
| Gabriele M. Cerrone Executive Chairman, Director | Oct 27, 2023 | Other | +70,071 | $1.50 | $105.11K | 9,177,903 |
| Gabriele M. Cerrone Executive Chairman, Director | Oct 23, 2023 | Other | +499,468 | $1.50 | $749.20K | 9,107,832 |
| John P. Brancaccio Director | Sep 15, 2023 | Buy | +16,670 | $1.50 | $25.01K | 16,670 |
| Gabriele M. Cerrone Executive Chairman, Director | May 19, 2022 | Buy | +5,800,000 | $0.08 | $464.00K | 548,981,215 |
| Gabriele M. Cerrone Non-Executive Chairman, Director, 10% owner | May 19, 2022 | Buy | +37,500 | $4.00 | $150.00K | 62,500 |
| Gary S. Jacob Chief Executive Officer, Director | May 19, 2022 | Buy | +12,500 | $4.00 | $50.00K | 12,500 |
| Gabriele M. Cerrone Non-Executive Chairman, Director, 10% owner | May 17, 2022 | Buy | +1,625,000 | $0.06 | $97.50K | 544,806,215 |
| Gabriele M. Cerrone Non-Executive Chairman, Director, 10% owner | May 17, 2022 | Buy | +25,000 | $3.87 | $96.75K | 25,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of OKYO Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 30,267 shares on Sep 22, 2026 over the last 90 days.
See a number that looks wrong?